Thirty-five adults underwent sequential PRK procedures in both eyes. In randomized order, each participant received oral CBD after one eye procedure and codeine-acetaminophen after the other.

The CBD regimen was 50 mg twice daily. The comparator was codeine 30 mg with acetaminophen 300 mg every four hours. Participants recorded pain and symptoms, and investigators assessed visual and quality-of-life outcomes.

Pain peaked on postoperative day 2 with both regimens. The abstract reports no statistically significant difference in mean or maximum pain ratings between treatments.

Visual acuity improved by month 3 without a treatment-related difference. Other symptoms and patient-reported outcomes were described as equivalent, although the abstract provides limited numerical detail.

A nonsignificant superiority test does not by itself prove that two treatments are noninferior or clinically equivalent. A formal noninferiority conclusion ordinarily requires a prespecified margin and confidence interval showing that the difference stays within that margin.

Those details are not reported in the PubMed abstract. Until the full statistical plan is reviewed, the safest description is that this small study detected no significant pain-score difference.

Sensorium scores were significantly higher when CBD was used after the first eye procedure, but not when it followed the second procedure. The authors interpreted this as a first-exposure effect.

That finding deserves practical attention because even mild subjective changes can matter for driving, work, medication combinations, and postoperative instructions.

The trial did not establish that CBD reduces opioid exposure across surgical care, works in other acute-pain settings, or matches non-opioid standards such as acetaminophen and NSAID-based regimens.

Larger blinded trials should report rescue medication, adverse events, clinically meaningful pain differences, noninferiority margins, confidence intervals, and patient-level preferences.

Postoperative opioid reduction is an important goal, but the relevant comparison is not simply CBD versus an opioid. Modern pain care often uses procedure-specific combinations of local therapy, acetaminophen, anti-inflammatory medication when appropriate, and limited rescue opioids.

CBD also varies across products. A studied low-THC oral formulation cannot validate untested retail products with different concentrations, contaminants, absorption, or labeling accuracy.

I find this trial worth attention because it asks a direct clinical question in humans and uses each participant as their own comparator. That is more useful than an anecdote or a mechanistic claim.

The responsible conclusion is still narrower than the abstract’s strongest language. Similar observed pain scores in 35 people are a signal for a larger trial, not a new postoperative standard.

A Four-Step Reading Frame